POSA236 Real-World Treatment (Tx) Characteristics for Advanced Non-Small Cell Lung Cancer (aNSCLC) Without Actionable Mutations After Introduction of Immune Checkpoint Inhibitors (ICIs) in EU4 and UK

Autor: Multani, J, Casey, V, Mpima, S, Yasuda, M, Chen, CC, Manuguid, F, Kalilani, L, Giove, TJ, Chao, J, Aziez, A, Stojadinovic, A, Hogea, C
Zdroj: In Value in Health January 2022 25(1) Supplement:S154-S155
Databáze: ScienceDirect
Externí odkaz: